VJHemOnc is committed to improving our service to you

EBMT 2020 | MGTA-145 with plerixafor for the mobilization and collection of HSCs

VJHemOnc is committed to improving our service to you

John DiPersio

John DiPersio, MD, PhD, Washington University, St. Louis, MO, discusses the use of MGTA-145, a novel, rapid mobilizing agent also known as truncated GRO-beta along with plerixafor for the mobilization and collection of hematopoietic stem cells (HSCs). In primate models, this combination resulted in the rapid mobilization of stem cells sufficient for autologous stem cell transplant and therefore could eliminate the use of granulocyte-colony stimulating factor (G-CSF). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter